Literature DB >> 16261833

Evaluation of cytokine production by equine alveolar macrophages exposed to lipopolysaccharide, Aspergillus fumigatus, and a suspension of hay dust.

Tamarinde T J M Laan1, Sarah Bull, R Scott Pirie, Johanna Fink-Gremmels.   

Abstract

OBJECTIVE: To evaluate cytokine production by equine alveolar macrophages after exposure to lipopolysaccharide (LPS), Aspergillus fumigatus, and hay dust, and determine the effect of clenbuterol on the cytokine response. ANIMALS: 6 horses. PROCEDURE: Alveolar macrophages were exposed to PBS solution (negative control), LPS, hyphae and conidia of Aspergillus fumigatus (AF), or a suspension of hay dust (HDS) and incubated for 24 hours at 37 degrees C. Concentrations of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta were measured in the supernatant. The procedure was repeated with cells that were concurrently incubated with 0.5 microM clenbuterol.
RESULTS: Exposure to HDS and AF significantly increased production of TNF-alpha by equine alveolar macrophages. The increase in TNF-alpha produced in response to HDS and AF was 5 and 7 times as great, respectively, as the increase measured in response to LPS. The concentration of IL-1beta in the supernatant was significantly increased after exposure of cells to AF. Clenbuterol was effective at inhibiting TNF-alpha production by cells exposed to LPS, HDS, or AF. CONCLUSIONS AND CLINICAL RELEVANCE: Increased production of TNF-alpha and IL-1 indicated that the pro-inflammatory cytokines produced by alveolar macrophages in response to allergens may play a role in recurrent airway obstruction (RAO) in horses. Equine alveolar macrophages are not only a primary pulmonary defense mechanism but may also influence the pathogenesis of equine RAO. The beta2-adrenoceptor agonist clenbuterol, a drug that is commonly used for treatment of equine RAO, promotes immediate bronchodilation and may also contribute to downward modulation of the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261833     DOI: 10.2460/ajvr.2005.66.1584

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

1.  Equine bronchoalveolar lavage cytokines in the development of recurrent airway obstruction.

Authors:  M Pietra; A Peli; A Bonato; A Ducci; S Cinotti
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

2.  Markers of respiratory inflammation in horses in relation to seasonal changes in air quality in a conventional racing stable.

Authors:  Miia Riihimäki; Amanda Raine; Lena Elfman; John Pringle
Journal:  Can J Vet Res       Date:  2008-10       Impact factor: 1.310

3.  Alveolar macrophage phenotypes in severe equine asthma.

Authors:  M E Wilson; E E McCandless; M A Olszewski; N Edward Robinson
Journal:  Vet J       Date:  2020-02-11       Impact factor: 2.688

Review 4.  Investigating the link between particulate exposure and airway inflammation in the horse.

Authors:  K M Ivester; L L Couëtil; N J Zimmerman
Journal:  J Vet Intern Med       Date:  2014-10-01       Impact factor: 3.333

5.  Immunohistochemical Expression of Neurokinin-A and Interleukin-8 in the Bronchial Epithelium of Horses with Severe Equine Asthma Syndrome during Asymptomatic, Exacerbation, and Remission Phase.

Authors:  Maria Morini; Angelo Peli; Riccardo Rinnovati; Giuseppe Magazzù; Noemi Romagnoli; Alessandro Spadari; Marco Pietra
Journal:  Animals (Basel)       Date:  2021-05-12       Impact factor: 2.752

6.  The equine alveolar macrophage: functional and phenotypic comparisons with peritoneal macrophages.

Authors:  Anna E Karagianni; Ronan Kapetanovic; Bruce C McGorum; David A Hume; Scott R Pirie
Journal:  Vet Immunol Immunopathol       Date:  2013-07-20       Impact factor: 2.046

7.  Comparative transcriptome analysis of equine alveolar macrophages.

Authors:  A E Karagianni; R Kapetanovic; K M Summers; B C McGorum; D A Hume; R S Pirie
Journal:  Equine Vet J       Date:  2016-07-09       Impact factor: 2.888

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.